Citadel Advisors
ARKG icon

Citadel Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Citadel Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.6M Sell
419,500
-286,100
-41% -$9.11M ﹤0.01% 2756
2026
Q1 		$18.6M Sell
705,600
-148,300
-17% -$4.34M ﹤0.01% 2412
2025
Q4 		$24.7M Sell
853,900
-51,700
-6% -$1.55M ﹤0.01% 2125
2025
Q3 		$25.1M Buy
905,600
+47,900
+6% +$1.21M ﹤0.01% 2047
2025
Q2 		$20.9M Buy
857,700
+49,800
+6% +$1.09M ﹤0.01% 2086
2025
Q1 		$16.8M Buy
807,900
+380,200
+89% +$9.55M ﹤0.01% 2229
2024
Q4 		$10.1M Sell
427,700
-246,900
-37% -$6.08M ﹤0.01% 2977
2024
Q3 		$17.3M Buy
674,600
+23,400
+4% +$596K ﹤0.01% 2205
2024
Q2 		$15.3M Sell
651,200
-281,900
-30% -$7.11M ﹤0.01% 2288
2024
Q1 		$26.8M Buy
933,100
+532,600
+133% +$16M 0.01% 1779
2023
Q4 		$13.1M Buy
400,500
+203,300
+103% +$5.53M ﹤0.01% 2490
2023
Q3 		$5.49M Sell
197,200
-47,800
-20% -$1.56M ﹤0.01% 3514
2023
Q2 		$8.35M Buy
245,000
+84,400
+53% +$2.65M ﹤0.01% 2907
2023
Q1 		$4.83M Buy
160,600
+35,300
+28% +$1.09M ﹤0.01% 3874
2022
Q4 		$3.54M Sell
125,300
-301,300
-71% -$9.56M ﹤0.01% 4478
2022
Q3 		$14M Sell
426,600
-267,400
-39% -$9.82M ﹤0.01% 2304
2022
Q2 		$21.9M Sell
694,000
-26,200
-4% -$916K 0.01% 1751
2022
Q1 		$33.1M Buy
720,200
+133,400
+23% +$6.36M 0.01% 1453
2021
Q4 		$35.9M Buy
586,800
+33,500
+6% +$2.32M 0.01% 1447
2021
Q3 		$41.3M Sell
553,300
-428,100
-44% -$35.9M 0.01% 1279
2021
Q2 		$90.8M Buy
981,400
+267,400
+37% +$22.7M 0.02% 724
2021
Q1 		$63.4M Buy
714,000
+276,300
+63% +$27.4M 0.02% 859
2020
Q4 		$40.8M Buy
437,700
+430,100
+5,659% +$34.3M 0.01% 1118
2020
Q3 		$484K Buy
+7,600
New +$445K ﹤0.01% 7356

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Citadel Advisors's ARKG Position: Q2 2026 in Review

Citadel Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2026, closing a stake of 294,157 shares — an estimated $9.37M sold.

Citadel Advisors first reported a position in ARKG in Q2 2018 and held it in 23 quarters. The position peaked at $22.9M in Q3 2021. 272 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Citadel Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 294,157 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $9.37M.
  • Citadel Advisors first reported a position in ARK Genomic Revolution ETF in Q2 2018 and held it in 23 quarters.
  • Citadel Advisors's ARK Genomic Revolution ETF position peaked at $22.9M in Q3 2021.
  • 272 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.